drugset
drugset / Trial / NCT06132243

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

NCT06132243 ↗

Phase 1 Completed 52 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the pharmacokinetic Characteristics of two formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers

Timeline

Start
2023-11-29
Primary completion
2023-12-20
Completion
2023-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 50 mg Oral

Indications

myelofibrosis